Trial Profile
A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs BCT 100 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Bio-Cancer Treatment International
- 05 Aug 2021 Status changed from discontinued to completed.
- 27 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
- 27 Jul 2017 Status changed from recruiting to discontinued for futility.